Targeted Oncology
Latest Publications

TOTAL DOCUMENTS

852

(FIVE YEARS 238)

H-INDEX

39

(FIVE YEARS 10)

Published By Springer-Verlag

1776-260x, 1776-2596

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Targeted Oncology ◽

10.1007/s11523-021-00865-8 ◽

2022 ◽

Author(s):

Monia Sisi ◽

Michele Fusaroli ◽

Andrea De Giglio ◽

Francesco Facchinetti ◽

Andrea Ardizzoni ◽

...

Keyword(s):

Adverse Reactions ◽

Kinase Inhibitors ◽

Reporting System ◽

Adverse Event Reporting System ◽

Adverse Event Reporting ◽

Small Cell Lung ◽

Event Reporting ◽

Anaplastic Lymphoma ◽

Spontaneous Reports

Download Full-text

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Targeted Oncology ◽

10.1007/s11523-021-00859-6 ◽

2022 ◽

Author(s):

Hai-Yan Tu ◽

Jifeng Feng ◽

Meiqi Shi ◽

Jun Zhao ◽

Yuyan Wang ◽

...

Keyword(s):

Final Analysis ◽

Download Full-text

Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study

Targeted Oncology ◽

10.1007/s11523-021-00860-z ◽

2021 ◽

Author(s):

David Waterhouse ◽

Laura Iadeluca ◽

Sneha Sura ◽

Keith Wilner ◽

Birol Emir ◽

...

Keyword(s):

Lung Cancer ◽

Observational Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Community Oncology

Download Full-text

Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Targeted Oncology ◽

10.1007/s11523-021-00864-9 ◽

2021 ◽

Author(s):

Matt Shirley

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

MYL-1402O: A Bevacizumab Biosimilar

Targeted Oncology ◽

10.1007/s11523-021-00858-7 ◽

2021 ◽

Author(s):

Arnold Lee

Download Full-text

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Targeted Oncology ◽

10.1007/s11523-021-00857-8 ◽

2021 ◽

Author(s):

Matt Shirley

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

B Cell Malignancies ◽

Bruton Tyrosine Kinase

Download Full-text

Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma

Targeted Oncology ◽

10.1007/s11523-021-00861-y ◽

2021 ◽

Author(s):

Veronica Mollica ◽

Matteo Santoni ◽

Marc R. Matrana ◽

Umberto Basso ◽

Ugo De Giorgi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Advanced Renal Cell Carcinoma

Download Full-text

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice

Targeted Oncology ◽

10.1007/s11523-021-00862-x ◽

2021 ◽

Author(s):

Lishi Lin ◽

Egbert F. Smit ◽

Adrianus J. de Langen ◽

Dorieke E. M. van Balen ◽

Jos H. Beijnen ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Practice ◽

Treatment Outcomes ◽

Cancer Patients ◽

Phase Iii ◽

Small Cell Lung ◽

Phase Iii Trial ◽

Lung Cancer Patients ◽

Download Full-text

Correction to: Durvalumab: A Review in Extensive-Stage SCLC

Targeted Oncology ◽

10.1007/s11523-021-00863-w ◽

2021 ◽

Author(s):

Zaina T. Al-Salama

Keyword(s):

Extensive Stage

Download Full-text

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Targeted Oncology ◽

10.1007/s11523-021-00855-w ◽

2021 ◽

Author(s):

Toshio Shimizu ◽

Yasutoshi Kuboki ◽

Chia-Chi Lin ◽

Kan Yonemori ◽

Tomoko Yanai ◽

...

Keyword(s):

Phase 1 ◽

Phase 1 Study ◽

Asian Patients ◽

East Asian Patients

Download Full-text